The role of HBV genotype core promoter and precore mutations in advanced liver disease in renal transplant recipients

Tsai, Ming-Chao; Chen, Chien‐Hung; Lee, Chuan–Mo; Chen, Yen-Ta; Chien, Yu-Yi; Hung, Chao‐Hung; Wang, Jing‐Houng; Lu, Sheng–Nan; Yen, Yi‐Hao; Changchien, Chi‐Sin; Hu, Tsung–Hui

doi:10.1016/j.jhep.2008.09.013

Cited by 14 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBeAg-positive and anti-HBe-positive findings were defined using S/Co ratios, in accordance with the manufacturer’s instructions (Abbott). Polymerase chain reaction and sequencing the HBV DNA polymerase gene mutations were done using nested PCR and direct sequencing as described previously [12]. The sensitivity of this method was 500 copies/mL.…”

Section: Methodsmentioning

confidence: 99%

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Lin

Chou

et al. 2013

Arch Virol

Self Cite

View full text Add to dashboard Cite

We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log10 IU/mL]: group 1, −0.149; group 2, -0.081; group 3, −0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log10 IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (−0.060 Log10 IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (−0.050 Log10 IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.Electronic supplementary materialThe online version of this article (doi:10.1007/s00705-013-1786-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Lin

Chou

et al. 2013

Arch Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data were obtained in an HBsAg-positive general population; however, if such results could also be reproduced in CKD, dialyzed patients, or RTRs is not known at present. As mentioned previously, Tsai et al [25] found a significant correlation between high serum HBV-DNA levels and the development of liver cirrhosis among RTRs. In that study, HBV replication was found to be enhanced by the presence of BCP as well as the pre-C mutations in the viral genome (HBeAg-negative variant).…”

Section: Hepatitis Bmentioning

confidence: 65%

“…Of those patients initially HBV-DNA positive, 55% had a significantly higher HBV-DNA level at the end of the follow-up. Among their patients, Tsai et al [25] found a similar profile (HBV-DNA initially positive and significantly higher replication at the end of the follow-up), with a high incidence of liver cirrhosis (67%).…”

Section: Hepatitis Bmentioning

confidence: 85%

Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients

Urbánek¹

2012

Kidney Blood Press Res

View full text Add to dashboard Cite

Within the last few decades, the incidence and prevalence of both hepatitis B and C infections have decreased among kidney disease patients. Significant advances have been made in the prevention of hepatitis B and C virus transmission in these high-risk populations; however, the transmission risk is still not negligible. Viral hepatitis infections represent a significant problem among kidney disease patients; patients on regular dialysis, as well as renal transplant recipients (RTRs) due to their epidemiological, virological, and clinical features. Chronic hepatitis B and C have a strong impact on the clinical course of kidney disease as well as on the clinical course after kidney transplantation. The purpose of this review is to focus on the epidemiology, transmission modes, natural courses, and treatment options of hepatitis B and C infections in both chronic kidney disease patients and RTRs.

show abstract

“…Pre-therapy HBV DNA was 6.3 and 8.68 Log 10 Eq/mL by branched DNA assay (bDNA assay) respectively, with detectable HBeAg in serum. ADV-based therapy was given for a median time of 15 months (range = [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. A significant reduction of serum HBV DNA occurred without changes in the HBeAg serologic status.…”

Section: Therapy Of Hepatitis B In Dialysis Patients: Adefovirmentioning

confidence: 99%

Management of Chronic Hepatitis B in Special Populations: Immunosuppressed Patients and Chronic Kidney Disease

2011

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection remains an important cause of liver disease in the population with chronic kidney disease, including patients on long-term dialysis and renal transplant (RT) recipients. Diminished survival due to hepatitis B has been observed after RT. A thorough evaluation, including liver biopsy as well as assessment of serum markers of HBV replication (ie, hepatitis B e antigen and/or HBV DNA) is required before transplantation. Tolerance to interferon is poor both in dialysis patients and after renal transplant. Oral antiviral therapy now permits safe and potent antiviral treatment of HBV-related liver disease in chronic kidney disease patients with prevention of progressive liver disease. Preliminary evidence shows an improved survival of HBsAg positive renal allograft recipients on antiviral therapy. However, numerous issues concerning the treatment of hepatitis B in the population with chronic kidney disease remain unclear and further clinical trials are needed.

show abstract

The role of HBV genotype core promoter and precore mutations in advanced liver disease in renal transplant recipients

Cited by 14 publications

References 38 publications

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients

Management of Chronic Hepatitis B in Special Populations: Immunosuppressed Patients and Chronic Kidney Disease

Contact Info

Product

Resources

About